PRMT5 attenuates regorafenib-induced DNA damage in hepatocellular carcinoma cells through symmetric dimethylation of RPL14.

ABSTRACT:

Background

Regorafenib has been approved for second-line treatment of hepatocellular carcinoma (HCC) following sorafenib failure, but resistance to targeted therapy remains a major challenge. Enhancing the therapeutic sensitivity of HCC cells to regorafenib is crucial for improving treatment outcomes. This study aims to elucidate the role of PRMT5 in HCC and its impact on regorafenib sensitivity. Specifically, it focuses on the regulatory relationship between PRMT5 and RPL14, investigating their influence on DNA damage repair and drug resistance mechanisms in HCC.

Methods

A stable PRMT5-overexpressing HCC cell line was constructed via lentiviral infection. Immunoprecipitation was employed to examine whether PRMT5 catalyzes the symmetric dimethylation of RPL14 at arginine res

SUBMITTER: Bi W 

PROVIDER: S-EPMC11921274 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature